Leuphasyl
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
A synthetic pentapeptide applied topically, marketed as a needle-free complement to Botox that eases facial muscle contractions to soften expression lines. Human evidence is limited: a small uncontrolled 20-person study reported wrinkle improvement, and combination-formulation studies cannot isolate the peptide's effect. Safety data is limited, though risks so far seem mild. It is a cosmetic ingredient, not an FDA-approved drug.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Leuphasyl (Pentapeptide-18) is a synthetic biomimetic peptide composed of five amino acids (Tyr-D-Ala-Gly-Phe-Leu) designed specifically for topical cosmetic use to reduce expression wrinkles. It belongs to the new generation of neurocosmetic active ingredients that target the neuromuscular mechanisms responsible for dynamic facial lines. Leuphasyl's amino acid sequence is inspired by enkephalins, the body's natural opioid neuropeptides that modulate nerve signal transmission.
The mechanism of action of Leuphasyl involves binding to enkephalin receptors on nerve cell surfaces, which modulates the release of acetylcholine at neuromuscular junctions. Acetylcholine is the neurotransmitter responsible for triggering muscle contraction. By partially reducing acetylcholine release, Leuphasyl diminishes the intensity of repeated micro-contractions that cause expression wrinkles around the eyes (crow's feet), forehead, and between the eyebrows. It is often compared to Botox in marketing, though its effects are far milder and it is applied topically rather than injected.
Argireline (Acetyl Hexapeptide-3/Hexapeptide-8) is another anti-wrinkle peptide that works through a different mechanism (inhibiting SNARE complex formation): Leuphasyl acts at the receptor level while Argireline acts intracellularly. Products containing both are marketed as a non-invasive alternative to botulinum toxin injections for consumers seeking topical anti-aging solutions.
How it works in the body
A synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu) that mimics enkephalin, binding to opioid receptors at the neuromuscular junction of facial muscles. This reduces acetylcholine release, decreasing muscle contraction intensity and smoothing expression lines. Works synergistically with Argireline (which blocks SNARE complex assembly).
Research overview
Leuphasyl (Pentapeptide-18) is a proprietary cosmetic peptide with research primarily from the cosmetics industry rather than peer-reviewed clinical medicine. The peptide was developed and patented by Lipotec (now part of Lubrizol/Berkshire Hathaway) as a topical alternative to botulinum toxin. Manufacturer studies claim up to 47% reduction in wrinkle depth when combined with Argireline over 28 days. A 2026 publication by Akhan et al. in Computational Biology and Chemistry (PMID 41722287) provided the first comprehensive academic characterization using DFT optimization, spectroscopic analysis (FTIR, ATR, Raman), molecular docking against key anti-aging targets (TGF-beta, TNF-alpha, MAPK, PI3K/AKT, NF-kB), and molecular dynamics simulations. Published independent clinical trials on Pentapeptide-18 specifically are limited. Most evidence is from proprietary manufacturer data and cosmetic formulation studies.
Who researches Leuphasyl?
Commonly researched by
People researching skin health and rejuvenation
Studied for collagen synthesis, skin repair, or anti-aging skin effects.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(2)
Rated by level of concern
Skin irritation or allergic reaction (rare)
LowPMID 42116636 (HaCaT cytotoxicity assay); no case reports identified in PubMed
Limited independent safety data
ModerateHuman tolerability information is limited to small topical studies, including Dragomirescu et al. 2014 and the 2024 retinol–pentapeptide-18 formulation study; long-term peptide-specific safety remains uncertain.
Interaction summary(7)
Rated by direction with this peptide
Acetyl Hexapeptide-8 (Argireline)
SynergisticTheoreticalThe two are proposed to act at different points of the same pathway — pentapeptide-18 presynaptically via opioid receptors, Argireline by interfering with SNAP-25/SNARE vesicle docking — so a complementary effect is mechanistically plausible, but the synergy has only ever been asserted in manufacturer literature, never demonstrated in a published combination study.
Mechanism-based; no peer-reviewed combination study in PubMed
Opioid receptor antagonists (naltrexone, naloxone; including topical/low-dose naltrexone)
CautionTheoreticalPentapeptide-18 is an enkephalin analogue whose proposed action is opioid-receptor agonism, so a co-applied or systemically active antagonist would be expected to blunt or abolish any effect — a pharmacodynamic antagonism worth noting, though never tested for this peptide. This is a loss-of-efficacy consideration, not a safety hazard.
Mechanism-based (enkephalin/DOR pharmacology); PMID 24830018 (Peripheral Opioids, in 'Itch: Mechanisms and Treatment', 2014 — opioid receptors in skin)
Topical retinoids (retinol, tretinoin, adapalene)
CautionLowRetinoids disrupt the stratum corneum barrier, which both increases irritation risk from any co-applied peptide and unpredictably increases its penetration; notably, published work has co-formulated retinol with pentapeptide-18 in solid lipid nanoparticles with acceptable physicochemical stability over four weeks at 4/25/45 C, so this is a tolerability caution rather than an incompatibility. Those papers report stability and skin-parameter outcomes, not toxicity testing.
PMID 39337562 (retinol + pentapeptide-18 solid lipid nanoparticles, stability data); PMID 39459512 (retinol + oligopeptide lipid nanocarriers)
Alpha/beta hydroxy acids, chemical peels, microneedling
CautionLowBarrier-compromising procedures and exfoliants substantially raise transcutaneous delivery of a peptide whose systemic and chronic-use profile is uncharacterized, and raise the chance of stinging or irritation on application; separating applications in time is the practical mitigation.
General topical pharmacology; no peptide-specific study
Botulinum toxin type A (injectable)
NeutralTheoreticalOften marketed as a complementary 'topical botox alternative' alongside or between injections, but there is no published study of concurrent use, and topical peptide delivery to the neuromuscular junction is itself unproven — so no clinically meaningful interaction should be assumed in either direction.
No published concurrent-use study identified
Systemic opioid therapy or opioid use disorder treatment (buprenorphine, methadone, naltrexone maintenance)
NeutralTheoreticalSystemic absorption from cosmetic topical application of a ~570 Da peptide is expected to be negligible and there are no reports of interference with opioid therapy, urine drug screening, or recovery — but this has never been formally studied, so patients in opioid recovery who are uneasy about an enkephalin analogue deserve a candid 'no data' answer rather than reassurance framed as evidence.
No pharmacokinetic or drug-screen interference data published for pentapeptide-18
Pruritus / chronic itch and atopic dermatitis management
CautionTheoreticalCutaneous opioid receptor signaling is directly implicated in itch, and delta-opioid signaling regulates keratinocyte proliferation, differentiation and barrier-gene expression, so chronic topical agonism in patients already being managed for pruritus or eczema is an untested variable that could plausibly modulate symptoms in either direction. No study has tested pentapeptide-18 in this setting.
PMID 24830018 (Peripheral Opioids — opioid receptors in skin and itch, 2014); PMID 25178105 (DOR affects epidermal homeostasis via ERK/POU2F3)
Known risks(2)
Skin irritation or allergic reaction (rare)
MildAs with any topical cosmetic ingredient, some individuals may experience redness, itching, or irritation. Patch testing is recommended for sensitive skin. No serious adverse events have been reported.
Limited independent safety data
Low (Unknown Long-Term)Most safety data comes from manufacturer assessments rather than independent clinical trials. The peptide has been on the market since ~2005 with no significant safety signals reported, but long-term independent studies are lacking.
Drug interactions(2)
Botulinum toxin injections (Botox, Dysport, Xeomin)
Theoretically additive neuromuscular modulation when used topically on areas treated with botulinum toxin. No adverse interactions reported, but the combination has not been formally studied.
Topical retinoids (tretinoin, adapalene)
May increase skin sensitivity and irritation when layered with retinoids. No pharmacological interaction expected. Standard cosmetic layering precautions apply.
Research & benefits
Evidence base
- Evidence Level
- Limited Evidence (Cosmetic Industry Data, Minimal Independent Clinical Trials)
- Total Studies
- 15
- Human Studies
- 100
The clinical evidence for Leuphasyl consists primarily of proprietary manufacturer studies from Lipotec and cosmetic formulation research. Independent peer-reviewed clinical trials are minimal. A 2026 computational study (PMID 41722287) provided academic validation of its molecular interactions with anti-aging targets, but this was in-silico/in-vitro only. The peptide is widely used in the cosmetics industry based on mechanistic plausibility and manufacturer efficacy claims rather than rigorous clinical trials.
Researched for(5)
Rated by confidence in the evidence
Reduction in expression wrinkle depth (manufacturer claims up to 47% combined with Argireline)
SpeculativeManufacturer's 47% figure is unpublished in-house data, not a peer-reviewed clinical trial.
The manufacturer's 47% figure needs its original dossier. Human evidence also includes Dragomirescu et al., Cosmetics 2014, n=20, and a 2024 retinol–pentapeptide-18 formulation study; neither establishes the 47% combination claim.
Modulation of neurotransmitter release to reduce muscle micro-contractions
SpeculativeProposed mechanism relies on general enkephalin pharmacology, not tested directly on skin or muscle.
No PubMed-indexed study of pentapeptide-18 at the neuromuscular junction; mechanism inferred from enkephalin/DOR pharmacology; PMID 42116636 (docking targets were MMPs/SIRT-1, not opioid receptors)
Synergistic anti-wrinkle effect when combined with Argireline (Hexapeptide-8)
SpeculativeNo published combination study, synergy claim rests on mechanism reasoning and manufacturer material.
No peer-reviewed combination study identified in PubMed; manufacturer claim only
Improved skin hydration and elasticity with topical application
SpeculativeSkin opioid-receptor biology is real, but hydration effects unproven for this specific peptide in humans.
PMID 16683988 (DOR knockout alters skin differentiation, delays wound healing); PMID 24628261 (DOR activation promotes wound healing via keratinocyte migration); PMID 25178105 (DOR affects epidermal homeostasis via ERK/POU2F3); PMID 39337562 (retinol + pentapeptide-18 SLN co-formulation)
Non-invasive topical application — no needles required
MediumTopical application is well established, though comparative efficacy versus injectables remains unverified in humans.
PMID 42116636 (no HaCaT cytotoxicity to 1 mg/mL); cosmetic ingredient (INCI Pentapeptide-18), not an injectable
Benefits(5)
Reduction in expression wrinkle depth (manufacturer claims up to 47% combined with Argireline)
Lipotec proprietary studies (28-day use); in-vitro muscle contraction models
Modulation of neurotransmitter release to reduce muscle micro-contractions
Mechanism-of-action studies based on enkephalin receptor binding
Often formulated with Argireline (Hexapeptide-8)
Lipotec combination studies; formulation industry data
Improved skin hydration and elasticity with topical application
Cosmetic formulation studies; Typology product development data
Non-invasive topical application — no needles required
Product formulation advantage vs. botulinum toxin injections
Key studies(2)
Pentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis
Computational / In-vitroN/A (in-silico)Akhan D, Bicak B, Akalin E, Kecel Gunduz S
Computational Biology and Chemistry
2026
First comprehensive academic characterization of Pentapeptide-18. DFT optimization, FTIR/ATR/Raman spectral analysis, and molecular docking against key anti-aging targets (TGF-beta, TNF-alpha, MAPK, PI3K/AKT, NF-kB) confirmed favorable binding interactions. Molecular dynamics simulations showed stable complexes. Computational ADMET analysis assessed predicted pharmacokinetic and drug-likeness properties; human pharmacokinetics were not measured.
Lipotec Leuphasyl Technical Dossier
Proprietary efficacy studyn=small cohort28 daysLipotec S.A. (Lubrizol)
Manufacturer Data (Proprietary)
2005
Topical Pentapeptide-18 (Leuphasyl) at 5% concentration reduced wrinkle depth in expression lines. When combined with Argireline (Hexapeptide-8), wrinkle reduction reached up to 47%. Mechanism attributed to enkephalin receptor-mediated inhibition of acetylcholine release.
Regulation & availability
Why researchers look at it
Leuphasyl offers a gentle, non-invasive approach to reducing expression wrinkles through topical neuromuscular modulation, making it appealing for consumers who want anti-aging benefits without needles or injections. It is often formulated with Argireline for use in a simple daily skincare routine.
- Estimated cost
- $15-50/mo in OTC serums
- FDA status
- Leuphasyl is a cosmetic ingredient, not an FDA-approved drug. FDA does not approve cosmetic ingredients before sale, and a product that claims to treat a condition or change how the body works is regulated as a drug. INCI listing identifies an ingredient name and does not certify compliance with EU Regulation (EC) No 1223/2009; finished products require appropriate safety assessment and compliance.
- WADA status
- Not specifically named in the 2026 WADA Prohibited List. Cosmetic use does not itself establish an anti-doping exemption. Compound-specific status and systemic absorption after topical use were not confirmed.
- Prescribability
- No — Over-the-counter cosmetic ingredient; does not require a prescription
- Availability
- Leuphasyl (Pentapeptide-18) is widely available as a cosmetic ingredient in anti-aging serums, creams, and eye contour products from numerous skincare brands. It does not require a prescription. Common product formulations include it at 2-5% in combination with Argireline and other anti-aging peptides. Available globally through retail skincare channels.
International status
EU
Available OTC in cosmetics (INCI listed)
US
Available OTC in cosmetic products (not a drug)
Worldwide
Regulated as cosmetic ingredient, not pharmaceutical
Regulatory timeline(5)
- ~2004Lipotec S.A. develops and patents Leuphasyl (Pentapeptide-18) as a cosmetic active ingredient
- 2005Leuphasyl launched commercially as a cosmetic ingredient; technical dossier published
- 2010sLeuphasyl becomes widely adopted in anti-aging cosmetic formulations globally
- 2012Lubrizol acquires Lipotec.
- 2026First comprehensive academic study published (Akhan et al., PMID 41722287)
Sources & FAQs
Research sources(4)
Frequently asked questions(3)
How does Leuphasyl compare to Botox?
Leuphasyl and Botox both aim to reduce wrinkles by modulating neuromuscular activity, but they work through completely different mechanisms and delivery methods. Botox is an injectable neurotoxin that paralyzes muscles; Leuphasyl is a topical peptide that mildly reduces acetylcholine release. Botox effects are dramatic and last 3-6 months; Leuphasyl effects are subtle and require consistent daily use. Leuphasyl is non-invasive but much less potent.
How does Leuphasyl differ from Argireline?
Leuphasyl acts at the enkephalin receptor level to reduce acetylcholine release, while Argireline acts inside the nerve terminal to prevent SNARE complex formation. Many commercial products contain both peptides.
How long does it take to see results from Leuphasyl?
Manufacturer data suggests visible wrinkle reduction within 15-28 days of consistent daily use. Effects are cumulative and require continued application. Results are subtle compared to injectable treatments and vary by individual.